Genmab reported 1.92B in Operating Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Agios Pharmaceuticals AGIO:US $ 100.52M 1.24M
Amarin AMRN:US 157.27M 34.34M
Amgen AMGN:US $ 4.42B 680M
Artemis Alpha ATS:LN 83.3M 3.9M
AstraZeneca AZN:LN 840.42B 39.99B
Bayer BAYN:GR 12.65B 2.22B
Biomarin Pharmaceutical BMRN:US $ 494.65M 112.61M
Bluebird Bio BLUE:US $ 108.92M 13.37M
Exelixis EXEL:US $ 335.72M 62.98M
Fresenius Medical Care FME:GR 4.42B 215.3M
Galapagos GLPG:NA 223.9M 58.73M
Genmab GEN:DC 1.92B 310M
GlaxoSmithKline GSK:LN 584.8B 95.1B
GN Store Nord GN:DC 4.46B 495M
Hikma Pharmaceutical HIK:LN 79.18B 796.93M
Immunogen IMGN:US $ 75.22M 14.28M
Insmed INSM:US $ 153.54M 10.6M
Lonza Group LONN:SW 2.34B 4M
Merck MRK:GR 4.39B 366M
Novartis NOVN:VX 10.86B 895M
Regeneron Pharmaceuticals REGN:US $ 1747.3M 40.7M
Seattle Genetics SGEN:US $ 630.61M 71.1M
William Demant Holding WDH:DC 7.91B 340M